Compare ACADIA Pharmaceuticals Inc. (ACAD) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs United States Natural Gas Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while United States Natural Gas Fund trades at $11.58. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| ACAD | UNG | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Commodities - Energy |
52-Week High | $28.06 | $16.90 |
52-Week Low | $20.06 | $10.15 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
UNG trades at $11.71, up 1.12% today, with a bullish technical signal driven by moving averages. The fund tracks natural gas futures, with sentiment influenced by weather-driven demand and LNG export flows. Recent news highlights volatility from storage data and production forecasts, while technical indicators like RSI remain neutral.
Outlook hinges on natural gas price trends, with upside from demand spikes but risks from contango and ample supply. Investors face structural challenges, as noted in analysis citing decade-long losses, requiring caution despite short-term bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
